Dr. Manish Gupta, an orthopaedic surgeon with a sports medicine focus enters as GID BIO’s newest principal investigator in a pivotal Phase III trial of
There is much to discover about how cell therapy has the potential to close the treatment gap between pain management and major surgery. Our research
In 2017, the Food and Drug Administration gave for-profit stem cell clinics three years to engage the regulatory approval process to establish the safety and
GID BIO CEO William Cimino, Ph.D., moderated the Industry Showcase panel at the recent 18th annual International Federation for Adipose Therapeutics and Science (IFATS) conference.
The proper surveillance of medical devices is necessary to ensure the health and safety of the public, and the Food and Drug Administration is committed
Listen to former NFL players Jaime Garza, MD, DDS, FACS, one of GID BIO’s principal investigators, and Jim Kovach, MD, JD, as they reunite on
As a company committed to proving the promise of regenerative medicine, GID continues to evaluate applications of its SVF-2 cellular implant platform clinically. One such
Only two years ago 484 companies were developing regenerative biologic therapies to treat a wide number of diseases and conditions [1]. Today even more companies
An interview with William W. Cimino, Ph.D. The beginning Ten years ago, the founders of GID were looking for a CEO. They made the
From the bark of the willow tree 3,500 years ago that Egyptians and Sumerians popularized for pain relief, medicine is one industry that can be
Sign up for our newsletter
